{"id":"NCT01173120","sponsor":"Bristol-Myers Squibb","briefTitle":"Methotrexate - Inadequate Response Device Sub-Study","officialTitle":"Sub-study-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2010-02","completion":"2010-07","firstPosted":"2010-07-30","resultsPosted":"2011-07-06","lastUpdate":"2012-01-12"},"enrollment":62,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis (RA)"],"interventions":[{"type":"DEVICE","name":"Abatacept combination product (ACP)","otherNames":["Orencia","BMS-188667"]}],"arms":[{"label":"Abatacept Combination Product (ACP)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.","primaryOutcome":{"measure":"Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation","timeFrame":"ACP substudy Day 1 to last substudy assessment occurring prior to the 1st dose of non-ACP subcutaneous (SC) abatacept, assessed up to 12 months","effectByArm":[{"arm":"Abatacept Combination Product (ACP)","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":62},"commonTop":["Bronchitis","Upper Respiratory Tract Infection"]}}